On Friday, the S&P/ASX 200 Index (ASX: XJO) once again finished the week deep in the red. The benchmark index sank 1.6% to 8,416.5 points.
Will the market be able to bounce back from this on Monday? Here are five things to watch:
Image Source: Getty Images
ASX 200 expected to rebound
The Australian share market looks set for a good start to the week following a positive finish to the last one on Wall Street. According to the latest SPI futures, the ASX 200 is expected to open the day 92 points or 1.1% higher. In the United States, the Dow Jones was up 1.1%, the S&P 500 rose 1%, and the Nasdaq pushed 0.9% higher.
Oil prices drop
It could be a poor start to the week for ASX 200 energy shares Santos Ltd (ASX: STO) and Woodside Energy Group Ltd (ASX: WDS) after oil prices dropped on Friday night. According to Bloomberg, the WTI crude oil price was down 1.6% to US$58.06 a barrel and the Brent crude oil price was down 1.3% to US$62.56 a barrel. This reflects optimism that Russia and Ukraine could soon sign a peace deal.
Pro Medicus update
Pro Medicus Ltd (ASX: PME) shares will be on watch today when the health imaging technology provider holds its annual general meeting. It is possible that the company will provide the market with a trading update ahead of the main event. Investors will no doubt be keen to see how quickly Pro Medicus is growing so far in FY 2026.
Gold price rises
ASX 200 gold shares Newmont Corporation (ASX: NEM) and Northern Star Resources Ltd (ASX: NST) could start the week higher after the gold price rose on Friday night. According to CNBC, the gold futures price was up 0.5% to US$4,116 an ounce. This was driven by increasing US rate cut bets in December.
Buy WiseTech shares
Bell Potter thinks that WiseTech Global Ltd (ASX: WTC) shares could offer 50%+ upside over the next 12 months. This morning, the broker has retained its buy rating on the logistics solutions technology company's shares with a trimmed price target of $100.00. It said: "In FY26 we now forecast revenue and EBITDA of US$1.40bn and US$569m which is towards the lower end of the guidance range for the former and close to the middle for the latter. That is, we see more risk at revenue than EBITDA this year, particularly with the greater-than-usual revenue skew to H2. Any weakness or miss at revenue, however, we would expect to be offset by a stronger margin."
